The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia

by Thaddeus L Miller, Andra Cirule, Fernando A Wilson et al.
Cost Effectiveness and Resource Allocation 2013, 11:9, (17 April 2013)

11 pp. 55 kB:

The authors compared the healthcare costs and treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) and non MDR-TB patients in Latvia to identify benefits or costs associated with both. They conclude that up to 2/3 of MDR-TB treated in their sample was preventable at a potential savings of over US$ 1.3 million in healthcare resources as well as substantial individual health.

(Visited 10 times, 1 visits today)
This entry was posted in General, Tuberculosis. Bookmark the permalink.